Reader Comments

The Oxidized Cholesterol Strategy

by regina fancy (2020-02-10)


Nobody dies of cholesterol; it is classed The Oxidized Cholesterol Strategy Review as a risk factor not a disease. Treating risk factors is good business, for the pharmaceutical industry. You are effectively getting life long customers, as "treatment" is long term. Compare this to an antibiotic maker. A person may need a course of an antibiotic but after one or two weeks that is it. You are off the drug.The other beauty of treating risk factors is that there is no downside. If someone on a cholesterol-lowering drug has a heart attack you cannot blame the drug as it was only lowering risk not treating anything. If you do not the drug maker will claim you as a success in their statistics.The most commonly used cholesterol lowering medications are the statins. These have been around for 20 years. Some of the early ones are now off patent and Lipitor, the biggest seller will be off patent in a few years. They are huge sellers having generated sales of hundreds of billions of dollars.So it is with interest that a new market is being opened for another statin drug, Crestor. This market of 6.5 million in the USA do not have raised cholesterol or any sign of heart disease but satisfy three other criteria for "risk" of heart disease, including age.This new use has FDA approval. Yet the same FDA is cautioning about the side effect of muscle damage with use of simvastain and has previously issued warnings about use of doses greater than 20mg in certain patient groups. A new trial has suggested statin drugs could increase the risk of Type 2 Diabetes.

 

https://healthreviewfactory.com/the-oxidized-cholesterol-strategy-review/





ISSN: 2338-8005